Vancouver, BC -- (SBWIRE) -- 01/19/2017 -- M Pharmaceutical Inc.,(the "Company" or "M Pharma"), announced today as part of its planned acquisition of 40 J's, that it will immediately seek marketing and distribution partnerships for its topical products for the relief of Diabetic Neuropathy symptoms.
"Diabetic Neuropathy, or diabetic nerve pain, is a result of permanent damage to the nerves of the hand and feet caused by elevated blood sugar levels. This pain is different from pain you may have experienced from arthritis, a headache or even a sports injury," said Gary Thompson, President and CEO of M Pharmaceutical USA. "Diabetic pain often times is so intense that it can affect the simplest of day to day activities for over 400 million people worldwide battling this disease. Our product's innovative topical formulations of menthol and L-arginine paired with other key ingredients has been shown to ease this hand and leg pain. Our goal is to have distribution contracts in place and product shipping by mid-summer," said Mr. Thompson.
About M Pharmaceutical Inc
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field.
Notice regarding Forward Looking Statements:
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company's biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices:
C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.